Previous Close | 26.55 |
Open | 26.58 |
Bid | 20.11 x 800 |
Ask | 28.02 x 800 |
Day's Range | 25.90 - 27.05 |
52 Week Range | 10.02 - 29.70 |
Volume | |
Avg. Volume | 317,370 |
Market Cap | 1.012B |
Beta (5Y Monthly) | 1.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.86 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 33.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for QTRX
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
BILLERICA, Mass., March 04, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effec
It's been a good week for Quanterix Corporation ( NASDAQ:QTRX ) shareholders, because the company has just released its...